Daiichi Sankyo Europe GmbH
9 products tracked · names used in filings: Daiichi Sankyo Europe GmbH
Upcoming milestones
No upcoming milestones listed.
Recent milestones
No recent milestones.
Products
| Product | Status | Approved | |
|---|---|---|---|
| 🇪🇺 | Datopotamab deruxtecan Daiichi Sankyo datopotamab deruxtecan | Application withdrawn | |
| 🇪🇺 | Vanflyta quizartinib | Refused | |
| 🇪🇺 | Turalio pexidartinib | Refused | |
| 🇪🇺 | Datroway datopotamab deruxtecan | Authorised | 2025-04-04 |
| 🇪🇺 | Vanflyta quizartinib | Authorised | 2023-11-06 |
| 🇪🇺 | Enhertu trastuzumab deruxtecan | Authorised | 2021-01-18 |
| 🇪🇺 | Nilemdo bempedoic acid | Authorised | 2020-04-01 |
| 🇪🇺 | Nustendi bempedoic acid;ezetimibe | Authorised | 2020-03-27 |
| 🇪🇺 | Lixiana edoxaban | Authorised | 2015-06-19 |
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.